NEW YORK, November 19, 2025 — Leads & Copy — Protara Therapeutics, Inc. (Nasdaq: TARA) will host a conference call and live webcast on Wednesday, November 19, 2025, at 8:30 a.m. ET to discuss new data from an interim analysis of the Phase 2 STARBORN-1 trial.
The STARBORN-1 trial is evaluating TARA-002, Protara’s investigational cell-based therapy, in pediatric patients with macrocystic and mixed cystic lymphatic malformations (LMs). The U.S. Food and Drug Administration has granted Rare Pediatric Disease designation to TARA-002 for the treatment of LMs.
TARA-002 is derived from the same master cell banks as OK-432, which was originally approved in Japan for treating LMs and has been the standard of care there for 30 years. OK-432 was also studied in a large Phase 2 trial involving over 500 LM patients, demonstrating significant clinical success. LMs are rare, congenital malformations of lymphatic vessels that prevent proper drainage into the venous system, commonly diagnosed in early childhood. These malformations can lead to airway obstruction, bleeding, nerve impingement, recurrent infection, and functional disabilities.
Protara Therapeutics is focused on developing transformative therapies for cancer and rare diseases. Its portfolio includes TARA-002 for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs), and IV Choline Chloride for patients on parenteral nutrition.
The live webcast and slides can be accessed at https://protara-therapeutics-update-call.open-exchange.net/registration, or through the Events and Presentations section of Protara’s website. A replay will be archived for a limited time.
Justine O’Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
Source: Protara Therapeutics, Inc.
